MARKET

STAA

STAA

Staar Surg
NASDAQ

Real-time Quotes | Nasdaq Last Sale

56.70
-1.73
-2.96%
After Hours: 55.62 -1.08 -1.90% 17:29 05/18 EDT
OPEN
56.63
PREV CLOSE
58.43
HIGH
57.97
LOW
55.36
VOLUME
495.99K
TURNOVER
4.20M
52 WEEK HIGH
163.08
52 WEEK LOW
49.03
MARKET CAP
2.71B
P/E (TTM)
96.30
1D
5D
1M
3M
1Y
5Y
3 Reasons Growth Investors Will Love Staar Surgical (STAA)
Staar Surgical (STAA) could produce exceptional returns because of its solid growth attributes.
Zacks · 1d ago
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Austin Gold (NYSE: AUST) shares rose 30.3% to $5.70 in pre-market trading after gaining around 9% on Wednesday. Austin Gold had its IPO on Wednesday at $5 per share.
Benzinga · 05/05 10:18
Staar Surgical (STAA) Q1 Earnings and Revenues Beat Estimates
Staar Surgical (STAA) delivered earnings and revenue surprises of 81.25% and 5.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 22:05
BRIEF-Staar Surgical Reports First Quarter Net Sales Of $63.2 Million Up 25% Y/Y
reuters.com · 05/04 21:53
Staar Surgical Q1 EPS $0.29 Beats $0.08 Estimate, Sales $63.20M Beat $60.53M Estimate
Staar Surgical (NASDAQ:STAA) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $0.08 by 262.5 percent. This is a 45 percent increase over earnings of $0.20 per share from the
Benzinga · 05/04 20:21
STAAR Surgical Non-GAAP EPS of $0.29 beats by $0.14, revenue of $63.2M beats by $2.67M
STAAR Surgical press release (NASDAQ:STAA): Q1 Non-GAAP EPS of $0.29 beats by $0.14. Revenue of $63.2M (+24.5% Y/Y) beats by $2.67M.
Seekingalpha · 05/04 20:03
STAAR Surgical Posts Higher Q1 Results Beating Street Views
MT Newswires · 05/04 16:48
-- Earnings Flash (STAA) STAAR SURGICAL COMPANY Reports Q1 Revenue $63.2M, vs. Street Est of $60.5M
MT Newswires · 05/04 16:19
More
No Data
Learn about the latest financial forecast of STAA. Analyze the recent business situations of Staar Surg through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

55.56%Strong Buy
22.22%Buy
22.22%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average STAA stock price target is 101.00 with a high estimate of 165.00 and a low estimate of 72.00.
High165.00
Average101.00
Low72.00
Current 56.70
EPS
Actual
Estimate
0.050.100.140.19
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 367
Institutional Holdings: 52.63M
% Owned: 110.07%
Shares Outstanding: 47.81M
TypeInstitutionsShares
Increased
105
2.39M
New
40
261.57K
Decreased
100
1.34M
Sold Out
46
478.90K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-2.72%
Healthcare Equipment & Supplies
-2.33%
Key Executives
Non-Executive Chairman/Independent Director
Louis Silverman
President/Chief Executive Officer/Director
Caren Mason
Chief Financial Officer
Patrick Williams
Senior Vice President
Hans-Martin Blickensdoerfer
Senior Vice President
James Francese
Senior Vice President
Graydon Hansen
Chief Technology Officer
Keith Holliday
Vice President
Jon Hayashida
Other
Scott Barnes
Secretary
Samuel Gesten
Independent Director
Stephen Farrell
Independent Director
Thomas Frinzi
Independent Director
Gilbert Kliman
Independent Director
Elizabeth Yeu
Independent Director
K. Peony Yu
No Data
No Data
About STAA
STAAR Surgical Company is a developer, producer, and marketer of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The Company's principal products are implantable Collamer lenses (ICLs) and intraocular lenses (IOLs). ICLs, consists of the Company’s ICL family of products, including the Toric implantable Collamer lenses (TICL) and EVO+ Visian ICL, are intraocular lenses used to correct refractive conditions such as myopia (near-sightedness), hyperopia (far-sightedness), astigmatism, and presbyopia. IOLs are prosthetic intraocular lenses used to restore vision that has been adversely affected by cataracts, and include the Company’s lines of silicone IOLs and the Preloaded Injector (a silicone or acrylic IOL preloaded into a single-use disposable injector). The Company sells its products in more than 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore.

Webull offers kinds of STAAR Surgical Company stock information, including NASDAQ:STAA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STAA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading STAA stock methods without spending real money on the virtual paper trading platform.